Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • General meetings
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
2 December 2021Regulatory Scandion Oncology announces share purchase by a member of the Board of Directors Download Presentation Webcast Workbook
1 December 2021Regulatory Scandion Oncology announce minutes of Extraordinary General Meeting Download Presentation Webcast Workbook
22 November 2021Regulatory Scandion Oncology announces share purchase by Board of Directors and Executive Management Download Presentation Webcast Workbook
18 November 2021Regulatory Scandion Oncology – Interim Report Q3 2021 Download Presentation Webcast Workbook
17 November 2021Regulatory Scandion Oncology announce notice convening an Extraordinary General Meeting Download Presentation Webcast Workbook
15 November 2021 Invitation to Scandion Oncology A/S webcast and conference call November 18, 2021 Download Presentation Webcast Workbook
12 November 2021Regulatory Scandion Oncology announce cancellation of extraordinary general meeting Download Presentation Webcast Workbook
8 November 2021Regulatory PANTAX study read-out postponed Download Presentation Webcast Workbook
2 November 2021Regulatory Scandion Oncology A/S: Notice convening an Extraordinary General Meeting Download Presentation Webcast Workbook
11 October 2021Regulatory Scandion Oncology A/S: Postponement of extraordinary general meeting Download Presentation Webcast Workbook
4 October 2021Regulatory Scandion Oncology A/S: Cancellation of extraordinary general meeting Download Presentation Webcast Workbook
21 September 2021Regulatory Scandion Oncology A/S: Notice convening an Extraordinary General Meeting Download Presentation Webcast Workbook
  1. Frontpage

About us

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Image library items
  • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.